What insurance policy changes affect code P07.03?

There are 3 tracked policy changes affecting code P07.03, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code P07.03?

Payers that have issued tracked updates for code P07.03 include: Aetna.

How do I get notified when code P07.03 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code P07.03. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code P07.03?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

P07.03 Insurance Policy Changes

ICD-10 P07.03 is officially defined as "Extremely low birth weight newborn, 750-999 grams." code P07.03 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code P07.03 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 10, 2026Medium impact
Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2026-10-07)
Aetna considers immune globulins medically necessary for hepatitis B, cytomegalovirus, Rho-D, rabies, varicella zoster, tetanus, vaccinia, botulism, hepatitis A, measles (rubeola) and rubella exposures or conditions, and considers all other indications experimental, investigational, or unproven. Each product has its own initial criteria, such as hepatitis B immune globulin for members who had contact with an individual diagnosed with hepatitis B virus, Rho-D immune globulin for unsensitized Rh-negative women at 24 to 28 weeks gestation unless the father is known to be Rh-negative, and varicella zoster immune globulin for high-risk individuals with significant exposure to varicella. Continuation of therapy for each product is considered medically necessary for all members, including new members, who meet all initial medical necessity criteria.
Aetna · Identified Aug 18, 2026Medium impact
T-Wave Alternans (CPB 0579, reviewed 2025-09-08)
Aetna considers microvolt T-wave alternans (MTWA) diagnostic testing using the spectral analytic method medically necessary for evaluating persons at risk of sudden cardiac death who meet criteria for implantable cardioverter-defibrillator placement. MTWA testing is experimental, investigational, or unproven for other indications, including diagnosis and risk assessment of acute coronary syndrome, guidance of anti-arrhythmic therapy, and evaluation of the adequacy of medical therapy. CPT 93025 is covered if selection criteria are met, but it is not covered for the diagnosis and risk assessment of acute coronary syndrome or for guiding anti-arrhythmic therapy.
Aetna · Identified Aug 15, 2026Medium impact
Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2025-12-23)
Reviewed 2025-12-23, Aetna Clinical Policy Bulletin 0544 covers immune globulin products for post-exposure prophylaxis and treatment, including hepatitis B, cytomegalovirus, Rho(D), rabies, varicella zoster, tetanus, measles, rubella, vaccinia, and botulism immune globulins. For each product the policy lists the indications it considers medically necessary and states that all other indications are experimental, investigational, or unproven. Continuation of therapy is considered medically necessary for all members, including new members, who meet the initial criteria. Immune globulin intramuscular injection (GamaSTAN) requires precertification.

Watch P07.03

Get one email when a payer policy names P07.03, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2026-10-07)

T-Wave Alternans (CPB 0579, reviewed 2025-09-08)

Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2025-12-23)

What insurance policy changes affect code P07.03?

Which payers have updated policy for code P07.03?

How do I get notified when code P07.03 policy changes?

Why do payers change policies for code P07.03?